Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy May 5, 2022 By Jesse Bufkin
A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection May 5, 2022 By Jesse Bufkin
Covered Cheatham Platinum Stent for Prevention or Treatment of Aortic Wall Injury Associated with Aortic Coarctation (COAST II) May 5, 2022 By Jesse Bufkin
Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group May 5, 2022 By Jesse Bufkin
An open, single-arm Phase II trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable, MAGE-A3 positive metastatic cutaneous melanoma May 5, 2022 By Jesse Bufkin
A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults with Recent-Onset Type 1 Diabetes Melli May 5, 2022 By Jesse Bufkin
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with May 5, 2022 By Jesse Bufkin
PHASE IV, OPEN-LABEL STUDY OF ORAL TESTOSTERONE UNDECANOATE IN HYPOGONADAL MEN May 5, 2022 By Jesse Bufkin
An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis May 5, 2022 By Jesse Bufkin
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF) (STAR-Too) May 5, 2022 By Jesse Bufkin
